Powder: -20°C for 3 years
In solvent: -80°C for 2 years
LNP023 hydrochloride is an orally bioavailable, highly potent and highly selective factor B inhibitor with an IC50 of 10 nM. LNP023 shows direct, reversible, and high-affinity binding to human factor B with a KD of 7.9 nM.
Description | LNP023 hydrochloride is an orally bioavailable, highly potent and highly selective factor B inhibitor with an IC50 of 10 nM. LNP023 shows direct, reversible, and high-affinity binding to human factor B with a KD of 7.9 nM. |
Targets&IC50 | factor B:10 nM, factor B:7.9 nM(KD) |
In vitro | LNP023 demonstrates excellent selectivity over other proteases affording IC50 values of >30 μM across a panel of 41 human proteases, including the AP protein factor D (>100 μM)[3]. |
In vivo | LNP023 (20-180 mg/kg; oral administration) is effective upon prophylactic and therapeutic dosing in an experimental model of membranous nephropathy in rats and prevents KRN (150 μL)-induced arthritis in mice[2]. After oral administration (rat 30 and, dog 10 mg/kg), LNP023 exhibits moderate half-lives (T1/2; Wistar Han rats 3.4 h, beagle dogs 5.5 h) and Cmax (Wistar Han rats 410 nM, beagle dogs 2200 nM)[3]. |
Synonyms | LNP023 hydrochloride, Iptacopan HCl |
Molecular Weight | 458.98 |
Formula | C25H31ClN2O4 |
CAS No. | 1646321-63-2 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
H2O: 50 mg/mL (108.94 mM), ultrasonic and warming
DMSO: 250 mg/mL (544.69 mM), Need ultrasonic
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Iptacopan hydrochloride 1646321-63-2 免疫与炎症 Complement System LNP 023 hemoglobinuria inhibit PNH atypical pathogenesis LNP023 hydrochloride Inhibitor LNP023 factor B system Iptacopan complement Iptacopan HCl paroxysmal syndrome LNP-023 pathway hemolytic uremic alternative nocturnal inhibitor